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Abstract
Primary immunodeficiencies (PIDs)* belong to the group of rare diseases which need more awareness by the 
relevant medical disciplines. Below a review on recent progresses in diagnosis and treatment of PIDs is given. 
Reducing the regrettable delay in diagnosis of PIDs (worldwide) is possible only when awareness is increased by 
doctors who may encounter patients with PID. This review shall serve this purpose. Progresses in understanding 
what the link might be between one genetic defect presenting in various phenotypes or how various gene defects 
may manifest by very similar PID phenotypes helps building awareness. Knowledge of PID favours early diagno-
sis, a cornerstone of optimal, sometimes life-long care at justifiable costs. The complexity of PIDs calls for clinical 
laboratory and clinical diagnostic performed by experts only. Exciting laboratory diagnostic progresses in early 
diagnosis of the most severe forms of PID are reviewed below. Progresses in curative therapies for PIDs, such as 
hematopoietic stem cell transplantation and gene therapies, are mentioned in short. About 80% of PID patients 
suffer from an antibody deficiency syndrome and can profit from non-curative replacement therapies with human 
immunoglobulin G concentrates. Modes of application, safety and hints for dosing of replacement therapies to re-
duce frequencies of severe infections are mentioned below. Thanks to the increasing quality of care, patients survive 
adolescence. A glance is given on the problems of transition to the adult medicine setting. 
* for abbreviations please consult the list of abbreviations at the end of the manuscript
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Progress in understanding the physio-
pathology of primary immunodficiency 
diseases
Primary immunodeficiencies (PIDs)*, in 
their majority, relate to an impaired capacity 
of patient’s immune system to fight infections, 
recurrent ones or infections with a very narrow 
range of pathogens (1). Some forms, when un-
treated, result in death early in life; others, in 
chronic debilitating infections and tissue re-
modelling. In addition, genetic defects identified 
more recently may result in an autoimmune-in-
flammatory phenotype of PID. Over 200 differ-
ent genetic defects leading to PIDs have been de-
scribed so far. With the progress of knowledge, 
the classification of PIDs has been updated regu-
larly. However, the most forefront classification 
also has become an issue of debates because for 
the everyday clinical work such classification 
has become a topic able to be overlooked by 
much specialised clinicians and researchers only 
(2-4).
Patients with recurrent, severe or unusual 
infections steadily are fuelling clinical research, 
thereby continuously increasing the number of 
genetic defects underlying PIDs (5;6). Under-
standing the pathogenesis of PID is essential 
for optimal therapy of PID patients and cost 
effectiveness of care. National and internation-
al registries are excellent sources for important 
information. Due to the increasing numbers of 
patients included to the various registries, more 
and more precise statements can be made on 
how an early, optimal and effective treatment of 
PID patients might become possible.
Definitions of rare disease in the EU and in 
the USA are: an incidence of ≤1/2000 (EU) or 
≤200,000 patients (USA). PIDs are rare diseas-
es with a prevalence of 5-6 patients per 100,000 
inhabitants in France (highest report in the EU) 
(7). A higher prevalence has been reported from 
countries with consanguine marriages (8). CVID 
is the most common phenotype of PIDs and em-
braces a heterogeneous group of patients which 
either suffer from infections only or in addition 
from inflammation, granuloma, autoimmunity, 
colitis, cytopenia and malignancy (9-12). Ten to 
twenty percent of the CVID phenotype have a 
familial trait and in about 3% of CVID 10 dif-
ferent gene defects or polymorphisms have been 
identified in the last 10 years (deficiencies of 
BAFF-R, CD19, CD20, CD21, CD81, ICOS, 
LRBA, MSH5, NF-κB2, PI3Kδ, and TACI) 
(13;14). In addition to CVID, haematological 
malignancies, autoimmune-like, inflammatory, 
and malignant conditions are comorbidities of 
many other PID phenotypes (15). 
Beside the classical PIDs, the non-classical 
PIDs are Mendelian conditions which are char-
acterized by a very narrow spectrum of oppor-
tunistic infections – sometimes limited to one 
microbial genus or species – while presenting a 
normal development of the principal leukocyte 
subsets. These non-classical PIDs comprise sus-
ceptibility to mycobacteria (10 genetic defects 
identified so far), predisposition to neisserial in-
fections (e.g. complement deficiencies) and in-
vasive bacterial disease, predisposition to inva-
sive fungal infections and chronic mucocutane-
ous candidiasis, predisposition to HPV infection, 
HSV encephalitis and EBV infection. 
The recognition and diagnosis of PID form 
beside of a clinician’s observation of an indi-
vidual clinical and/or immunological phenotype 
remains difficult. Therefore, attempts to provide 
guidelines for clinicians at the bedside were pub-
lished recently (16).
PID diagnosis - As early as possible
Shortening the delay in diagnosis of PID is 
the key for cost-effective therapies and is help-
ing to keep health care costs reasonable without 
restricting patients’ access to the relevant thera-
pies (17;18). The platform for early diagnosis is 
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medical awareness. To increase awareness in all 
medical disciplines that may encounter patients 
with PID and the wide spreading of the ‘warn-
ing signs of primary immunodeficiency’ can be 
an effective tool (19;20). However, it has to be 
stressed that for taking the correct actions the 
widely promulgated “warning signs” have to be 
interpreted by experts (21). Other tools to raise 
awareness might be medical discipline-specific 
reviews (22-26) or data mining in national or in-
ternational registries. National registries may not 
have the power of international registries (http://
esid.org/Working-Parties/Registry/ESID-On-
line-Registry, accessed April 2014).
Hints for PID need a follow-up by standard 
diagnostic measures, e.g.  serum immunoglobu-
lin isotype levels plus specific response to vac-
cination, small lymphocyte panel plus B cell 
panel plus CD45RA CD4 T cells (+ T cell pro-
liferation) (27). If the results are not conclusive, 
the next level might include specific membrane 
protein detection by fl ow cytometry (28-30). Es-
tablished diagnostic criteria for SCID variants 
and recently published guideline for new-born 
screening are available (31;32).
Combined immunodeficiencies (CIDs) need 
to be recognized and separated from CVID. 
CIDs are T-cell impairments and can manifest as 
infections by intra/extracellular “opportunistic 
agents”. Even though sharing common clinical 
features, the discovery of new causative gene 
alterations led to the identification of novel com-
plex clinical phenotypes of CID, with manifesta-
tions of autoimmunity/inflammation, allergy and 
lymphoma. CIDs represent about 20% of PIDs 
with approximately 80 different gene alterations 
(prevalence according to the French registry 
1.1/100,000 or ~1/20,000 births). The detection 
of these alterations relies on nucleic acid se-
quencing methods and can prevent the death of 
affected children. 
Population-based new-born screening (NBS) 
is a promising technique to detect from Guth-
rie cards severe combined immunodeficiency 
(SCID) or combined immunodeficiency (CID) 
based on the T-cell receptor (rearrangement) ex-
cision circles (TREC) assay (33). At present, the 
cut-off of the test is a problem because a wide 
spectrum of detected non-SCID disorders with 
T-cell lymphopenia. Although an evaluation of 
the population based SCID-NBS outside the 
US has started, and despite the proof of cost ef-
fectiveness of SCID-NBS, issues such as costs, 
ethics, moral, social, legal and policy remain 
the main barrier against wide implementation in 
countries other than the USA.  Performing the 
TREC assay only might miss some forms of se-
vere PIDs (34). 
The potency of the population-based NBS 
for PIDs can be enhanced by introduction of 
the κ-deleting recombination excision circles 
(KREC) assay which allows for additional de-
tection of B cell lymphopenia (35;36). The 
combination of both tests considerably expands 
the diagnostic range at a cost increase of about 
0.10 Euro only. Furthermore, information from 
of TREC and KREC levels can also been used 
as a surrogate marker of lymphocyte output in 
acquired immunodeficiencies and it also might 
allow to follow therapy success (37). Laboratory 
methods for population-based dried spot analy-
ses are expanding rapidly. Extension of the mass 
screening for PIDs not detectable by TREC and 
KREC assay might come at low cost from dried 
blood sample analysis by mass spectrometry 
(38)
The clinical and immunologic heterogeneity 
of CVID remains a diagnostic challenge (39;40). 
Recently a heterogeneous group of patients was 
classified according to B cell phenotype, KREC 
analysis, and SHM pattern. Five B-cell patterns 
were identified each reflecting an immunologi-
cally homogenous patient group with proposed 
unique pathophysiology. Another diagnostic 
challenge is the differential diagnosis between 
particular forms of CVID and CID. Time will 
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show whether the TREC, KREC assay or ge-
nome wide array analyses might be helpful in 
understanding clinical heterogeneity of CVID 
and dissect it from CID (14;41).
In 2006 the generation of “induced pluripo-
tent stem cells” (iPSC) was reported for the first 
time by  epigenetically reprogramming of so-
matic cells through the exogenous expression of 
transcription factors. The technique then could 
be adapted to human fibroblasts (42;43). Induced 
pluripotent stem cells (iPSCs) offer a unique po-
tential for understanding the molecular basis of 
diseases and disease development. The study of 
primary immunodeficiencies (PIDs) has largely 
been based on animal models, in-vitro assays, 
and was suffering from the limited access to 
disease-specific tissue. Application of this tech-
nique one day might become an additional tool 
for functional investigation of human PIDs and 
other disorders as well as it might provide new 
medicines (44). 
Optimizing replacement therapies at 
high safety levels
Immunoglobulin replacement therapies are 
the therapy of choice for the majority (~80%) 
of PID patients. Replacement therapy is not cu-
rative but can ensure over long-term acceptable 
Quality of Life. Depending on the country, there 
is a more or less broad offer of various immuno-
globulin concentrates available (http://www.ip-
opi.org/index.php?page=immunoglobulin-com-
panies; accessed May 2014).
Treatment of PID, as any other rare disease, 
requires expertise. A recent study in the northern 
hemisphere compared management of patients 
dependent on replacement therapies. US physi-
cians with >10% of their practice devoted to pri-
mary immunodeficiency managed PID therapy 
very similarly to their colleagues in EU, while in 
US physicians whose clinical practice was com-
posed of <10% of PID patients management pro-
tocols differed from the other two groups (45). 
Low percentage of PID patients treated in clinic 
or practice may not optimally comply with pa-
tients’ need.
According to the American Academy of 
Allergy, Asthma and Immunology (AAAAI), 
replacement therapy is definitively beneficial 
for PIDs with absent B cells and PIDS with hy-
pogammaglobulinaemia and impaired specific 
antibody production; it is probably beneficial for 
PIDs with normogammaglobulinaemia and im-
paired specific antibody production; and unlike-
ly to be beneficial for isolated IgA and IgG4 defi-
ciency (46). According to the EU PID Consensus 
Conference outcomes, the indication for replace-
ment therapy is given for all patients with IgG of 
< 2g/L - with the exception of children without 
severe infectious complications (physiological 
hypogammaglobulinaemia of childhood); at lev-
els of 2-5 g/L when associated with recurrent in-
fections; and with IgG of > 5g/L when there is a 
deficiency in the formation of antibodies to spe-
cific antigens and serious or recurrent infections 
(http://ec.europa.eu/health/ph_projects/2005/
action1/docs/action1_2005_exs_01_en.pdf; ac-
cessed April 2014). 
In an environment of ever increasing use of 
immunoglobulin concentrates it has to be ascer-
tained that PID patients have now and in future 
a continuous and sufficient access to this plasma 
derived medicinal product (47). Treatment based 
on evidence based practice guidelines (48;49) 
and Prioritisations Plans, of which the most have 
been compiled into a European consensus pro-
posal (50), are valuable tools for an appropriate 
use and the best prioritisation of Ig concentrates 
in and outside the PID field. These documents 
can be adapted e.g. to the needs of Romanian pa-
tients and care givers. 
The proportion of patients receiving SCIG 
is continuously increasing: new products, less 
frequent adverse events, sustainably higher im-
munoglobulin levels in the circulation and the 
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option of easy to perform home therapy thereby 
possibly reducing costs, at least in certain coun-
tries, support this development (51-54). SCIG 
can be applied with the help of a pump e.g. every 
two to three days, weekly, and three weekly to 
monthly facilitated by hyaluronidase or daily by 
“rapid push” (55-57). Availability of IVIG and 
SCIG allows for adapting replacement therapy 
to the clinical situation and the preference of the 
treating physician and/or how it is best suitable 
for the patient’s individual needs (58). However, 
SCIG should be applied with care when risk fac-
tors exist (e.g. severe thrombocytopenia, bleed-
ing disorders or anticoagulation therapy).
Dosing levels in replacement therapy are an 
eternally discussed topic. As a rule it is accept-
ed that increasing the dose reduces risk for se-
vere infections and this is true for the i.v. and 
the s.c. route of application of immunoglobulins 
(59;60). In a naïve patient, or a patient not hav-
ing received replacement therapy for more than 
3 months, the aim is to increase circulating IgG 
rapidly and this is achieved best by initially slow 
infusion via the i.v. route with doses starting at 
0.4-0.6 g/kg b.w./3-4 weeks. Furthermore, evi-
dence-based medicine data indicate as a rule that 
trough levels above 5-6 g IgG/L being “effec-
tive”. However, there are patients who are not 
able to cope with these rules. Parameters iden-
tified so far for not being able to cope with the 
rules are (i) patient’s residual levels of IgA, (ii) 
serum concentration of mannose-binding lectin, 
(iii) the polymorphism of the neonatal FcRn re-
ceptor, and (iv) B cell defects  (61-65). In some 
patients the optimisation of replacement therapy 
might require measurement of e.g. anti-pneu-
mococcal antibodies. An optimal maintenance 
therapy of PID patients is “individualized” and 
does not follow through levels and is not weight 
based, i.e. a biological level should be achieved 
and this level might need adaptation in winter- 
versus summer-time (66). 
When shifting from IVIG to SCIG difference 
exist what US and European authorities consid-
er as adequate (67;68). In daily practice and in 
general, mean actual levels of circulating IgG in 
patients has risen over the decades, and due to 
several factors tend to be higher when on SCIG. 
Furthermore, steadily increasing mean levels of 
IgG in the circulation of PID patients are driven 
by deeper insight into pathophysiology. Particu-
larly autoimmune and inflammatory conditions 
associated with antibody deficiency syndromes 
may support orientation towards treatment doses 
corresponding to those applied for immunomod-
ulation. Some caution is advised when discuss-
ing trough levels. Because of the difference in 
application intervals and doses, pharmacokinet-
ics differs and trough levels might not be directly 
comparable. 
Therapy of antibody deficiency syn-
dromes-associated non-infectious  
complication
Beside recurrent respiratory and gastroenter-
ic infections, autoimmune-like, inflammatory 
and malignant conditions in a part of PID pa-
tients are associated with increased mortality and 
pose major clinical challenges. The background 
for these complications remains unknown. For 
CVID differences in peripheral T- and B-cell 
compartments of patients might have some influ-
ence, i.e. disease-related complications appear 
to be more frequent in patients with naive CD4+ 
T-cell defects (69). Optimal treatment of dis-
ease-related complication in CVID remains an 
unmet medical need (9;70). Treatment needs ex-
pertise to take the decision for watchful waiting 
vs active therapy if available at all. Some ther-
apy options might be optimal IgG substitution, 
supportive therapy (parenteral nutrition), antibi-
otics, corticosteroids / Budesonide, immunosup-
pressive therapy (Methotrexate, Azathioprine, 
biosimilars (Rituximab, Infliximab), and trans-
plantation. It remains unclear how far the com-
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plications are infection-related/triggered. Multi-
centre (observational) studies and data mining in 
registries are required to obtain answers on how 
best to treat these conditions.
Transition of PID patients to the clinic for 
adults
Transition, i.e. the purposeful, planned 
movement of adolescents and young adults with 
chronic physical and medical conditions from 
child-centred to adult-oriented health care sys-
tems, is a long-haul interdisciplinary project and 
remains an unresolved problem (71). Particular 
centres for PID/rare diseases might be best suit-
ed in supporting patients on their sometimes dif-
ficult journey into adulthood by e.g. establishing 
a “transition clinic”. After the transition phase 
or PIDs with late onset diseases/late diagnosed 
disease, patients might be confronted with dif-
ficulties to access specialists and obtain optimal 
therapy. Very recently, a scoring system was pre-
sented how to establish replacement therapy in 
adult PID (72).
Pathogen safety of replacement therapy
Measures requested by authorities such as 
current Good Manufacturing Practice (cGMP) 
and voluntary quality standards implemented 
by the plasma fractioning industry have pushed 
pathogen safety of immunoglobulin concen-
trates high and this is indicated by no reports of 
transmission of emerging viruses (SARS CoV, 
West Nile Virus and others), zoonotic pathogens 
or the agent of variant Creutzfeldt-Jacob disease 
in the last decade (73;74). 
Adverse events related to replacement  
therapy
Adverse events to IVIG and less frequently 
to SCIG in their majority are mild to moderate 
in intensity and largely self-limiting. Adverse 
events to therapeutic immunoglobulin concen-
trates might be related to the active component 
IgG, to impurities or to excipients in the prepa-
rations. The active component-related adverse 
events are inherent to replacement therapy. In-
herence in part is due to the nature of our im-
mune system, which on one hand serves host 
defence and on the other hand it also is part of 
the peripheral immunologic homeostasis net-
work and serves removal of altered and senes-
cent self. IgG concentrates derive from the im-
mune system of several thousand healthy do-
nors. Their application in patients results in the 
desired recognition and subsequent removal of 
possible pathogens but inevitably also results 
in the recognition of the recipient’s variable-re-
gion connected immune network (75) and the 
recognition of altered or senescent tissue in an 
alloimmune fashion (76). This type of adverse 
events, as a consequence, is more patient than 
product dependent. Frequency of adverse events 
after IVIG infusion usually can be kept low by 
low infusion rates and avoiding some excipients 
in IVIGs (77). Severe adverse events are acute 
renal failure manly due to osmotic nephrosis 
(predominantly by excipient), anaphylaxis, i.e. 
interaction of co-fractionated IgA in the prod-
uct (impurity) with anti-IgA very rarely present 
in the plasma of the patient, aseptic meningitis, 
haemolysis i.e. due to anti-blood group antibod-
ies (impurity), TEEs i.e. due to FXIa (impurity) 
and transfusion-related acute lung injury (78). 
Reports on increasing numbers of haemolysis 
and TEEs with severe consequences are a re-
cent focus of concern. Both types of AEs are 
strongly related to the dose applied. TEEs have 
been found to be associated with elevated lev-
els of activated coagulation factor XI (FXIa) and 
kallikrein (79) and resulted in the batch-wise 
testing and removal of FXIa (http://www.web-
medcentral.com/article_view/2002; accessed 
April 2014). Despite all measures, patient- and 
administration-related factors for TEE remain; 
risk factors are age, underlying disease, co-mor-
bidities, high protein doses and rapid infusion. 
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Haemolysis is a long recognized complication of 
IVIG therapy occurring at an apparent frequen-
cy of <1/100,000 patients treated and has been 
observed with intramuscular, subcutaneous and 
predominantly with intravenous preparations. 
In the last decade an increase in haemolysis 
rates were observed when infusing certain IVIG 
brands at immunomodulatory doses (80)while in 
a review of IVIG replacement trials an increase 
in direct Coombs test was observed without ev-
idence of haemolysis (81) (for the courtesy of 
the reader: Gammagard liquid (US) corresponds 
to KOIVIG (EU)).  Haemolysis can manifest as 
haemolytic anaemia or in isolated cases as hae-
molysis-related renal dysfunction/renal failure 
or disseminated intravascular coagulation and 
death. Isoagglutinins, e.g. A, B and AB have 
been attributed to mediate these higher frequen-
cies (82) although release criteria of US & EU 
products include specifications for anti-A & an-
ti-B antibodies of </= 1:64 in the direct haem-
agglutinin assay. As IVIG-associated haemolysis 
occurs although products meet licensed specifi-
cations risk factors other than isoagglutinins are 
supposed, e.g. inflammatory conditions and rap-
id infusion. Meanwhile the plasma fractionating 
industry has taken measures to reduce isoagglu-
tinin levels in immunoglobulin concentrates, 
e.g. by withholding from pooling high-titre do-
nations and/or by introducing a polishing step 
which reduces isoagglutinins by immunoaffinity 
chromatography. 
Vaccination and PID
Vaccination can be an excellent diagnostic 
tool in PID. Otherwise, PID vaccination cannot 
have a universal role because the difference in 
the various forms of PIDs. In patients with low 
antibody production vaccination might be con-
sidered in order to minimize the recurrence of 
episodes of infection using killed pathogens or 
subunits (refrain from the vaccination with (at-
tenuated) live vaccines!). There are only very 
few controlled studies reported with most data 
generated in children. The grade of treatment rec-
ommendation drawn from these studies remains 
C (possible effective; 2nd or 3rd line treatment) 
and in rare cases it might reach recommendation 
grade B (possibly effective, use as alternative to 
other therapy options). After having consulted 
a PID specialist, vaccination may be performed 
(www.cipo.ca/Vaccines.doc; accessed June 
2014). Thus, dead influenza vaccine is safe, can 
be applied for seasonal prophylaxis but may not 
work well in patients with CVID while patients 
with IgA deficiency might profit from it. Howev-
er, clinical improvement might be observed even 
in absence of detectable increase of protective 
antibody levels and this has resulted in best prac-
tice statement from the UK (http://www.rcpch.
ac.uk/sites/default/files/asset_library/Publica-
tions/I/Immunocomp.pdf; accessed June 2014) 
and uncertainties together with the growing ne-
glect of societal adherence to routine immuniza-
tions has prompted the Medical Advisory Com-
mittee of the Immune Deficiency Foundation 
(US) to issue recommendations based on pub-
lished literature and the collective experience of 
the committee members (83). The prophylactic 
vaccination of household members of these pa-
tients groups is highly recommended.
Curative therapies for PID
Haematopoietic stem cell transplantation / 
bone marrow transplantation 
Between 1968 and 2012 more than 2250 
transplantations for SCID and more than 5000 
for non-SCID PIDs have been performed (84). 
The methods applied are bone marrow transplan-
tation, cord blood transplantation and machinery 
supported collection of HSCs. Very early trans-
plantation (indicated by family history or pop-
ulation-based NBS) significantly improves out-
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come irrespective of donor choice, conditioning 
regimen used, and underlying genetic diagnosis. 
Other factors of steadily and incrementally im-
proving HSCT outcome encompass reduced in-
tensity condition regiment, increasing expertise 
in ablation of certain donor cell populations in 
order to provide a balance between engraftment 
and graft-versus-host disease (GvHD), low dose 
serotherapy new drugs allowing reduction of 
veno-occlusive disease, close viral and fungal 
surveillance, and more sophisticated supportive 
care (85-87). Very recent US NBS data indicate 
that a prolonged time window for transplanta-
tion might be gained when timely TREC-NBS 
prompt immediate measures to avoid infections 
and organ damage. Transplantation in some CID 
can pose a considerable challenge as infection, 
autoimmunity/inflammation, allergy and lym-
phoma have to be taken into account.
Post HSCT viral infections are (severe) 
complications and also pose a major therapeutic 
challenge. Emerging therapies are Rituximab for 
EBV and CMX010 for CMV infections.
Patient-derived induced pluripotent stem 
cells
The iPSC technique allows the access to 
previously inaccessible diseased tissue and in 
turn allows the development of novel treatment 
strategies such as has been reported for X-linked 
CGD (88).
Gene therapy
Gene therapies are curative measures for 
PIDs (89-91). They belong to the emerging 
group of “personalised” therapies. Site-specific 
insertion and the development of safe and ef-
fective self-inactivating viral vectors have re-
duced the risk for post-transplant malignancies 
(insertional oncogenesis). The process involves 
the isolation of autologous haematopoietic stem 
cells (HSC), ex vivo introduction of the gene of 
interest by viral vector, expansion of cells and 
‘transplantation’ of the gene-corrected HSC 
(92). The recent vectors are retroviruses, SIN 
retroviruses and lentiviruses engineered to have 
no potency for insertional oncogenesis (91;93). 
PID conditions treated so far or being in clini-
cal studies are SCIDX1, ADA-SCID, CGD, and 
WAS. For the future all PID patients identified 
with genetic defects are potential candidates for 
gene therapy (94). This includes those 10 gene 
defects with the ‘CVID’ phenotype which have 
been identified in the last 10 years (see above). 
Attempts for scientific assessment for marketing 
authorization of ‘advanced therapy medicinal 
products’, e.g. of viral vectors based gene thera-
pies, have been initiated (http://www.ema.euro-
pa.eu/ema/index.jsp?curl=pages/about_us/gen-
eral/general_content_000126.jsp&mid=WC-
0b01ac05800292a5; http://ec.europa.eu/health/
human-use/advanced-therapies/developments/
index_en.htm; http://www.genetherapynet.com/
europe.html; all accessed June 2014).
Conclusions
Developments in understanding pathogene-
sis, diagnosis and therapy of PIDDs have pro-
gressed rapidly in the recent years. Particular 
note has to be given to the new screening tech-
niques allowing diagnosis at a time point where 
no organ damage has occurred yet. Nevertheless, 
some problems remain such as the low aware-
ness for PID or the emergence of complex eth-
ical problems due to the new diagnostic tools. I 
hope this short review helps raising awareness 
for a rare disease where for a large part of the 
patients satisfying therapy options exist.
List of abbreviations
BAFF-R: B cell activating factor receptor (of the 
tumour necrosis factor family); tumour necrosis 
factor receptor superfamily member 13C; TN-
FRSF13C
BMT: bone marrow transplantation
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CD: cluster of differentiation
CID: combined immunodeficiency
cGMP: current good manufacturing practice
CMV: cytomegalovirus
CVID: common variable immunodeficiency
EBV: Epstein-Barr virus
ESID: European Society for Immunodeficien-
cies
FcRn: Fc receptor of the newborn; Brambell re-
ceptor
GvHD: graf-versus-host disease
HPV: human papilloma virus
HSCT: hematopoietic stem-cell transplantation
HSV: herpes simplex virus
ICOS: inducible (T-cell) co-stimulator
iPSC: induced pluripotent stem cells
IVIG: human immunoglobulin G concentrate 
applicable via the intravenous route
KREC: κ-deleting recombination excision circle
LRBA: lipopolysaccharide-responsive and 
beige-like anchor protein
MSH5: human homolog of Escherichia coli 
MutS 5
NBS: new-born screening
NF-kB: nuclear factor kappa-light-chain-en-
hancer of activated B cells
PI3Kd: phosphatidylinositol-3-OH kinase PI(3)
K catalytic subunit delta
PID: primary immunodeficiency
PIDD: primary immunodeficiency disease
SARS-CoV: severe acute respiratory syndrome 
corona virus
SCID; severe combined immunodeficiency 
SCIG: human immunoglobulin G concentrate 
applied via the subcutaneous route
SHM: somatic hyper mutation
SIN: self-inactivating 
TACI: transmembrane activator and calcium 
modulator cyclophilin ligand interactor;  tumor 
necrosis factor receptor superfamily member 
13B; TNFRSF13B; 
TEE: thromboembolic event
TREC: T-cell receptor (rearrangement) excision 
circle
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